View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Hubspot Inc: 1 director

A director at Hubspot Inc sold/sold after exercising options 3,937 shares at 616.510USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...

 PRESS RELEASE

Semtech Announces First Quarter of Fiscal Year 2025 Conference Call

CAMARILLO, Calif.--(BUSINESS WIRE)-- (Nasdaq: ), a high-performance semiconductor, IoT systems and cloud connectivity service provider, announced plans to release the financial results of its first quarter of fiscal year 2025 after the close of the market on Wednesday, June 5, 2024. The results will be released through Business Wire and posted at . Semtech will host a conference call at 2 p.m. PT (5 p.m. ET) Wednesday, June 5, 2024, to discuss its first quarter of fiscal year 2025 performance and events, current business activities and conditions, and the outlook for the business. Participa...

 PRESS RELEASE

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics Announces Board Chair Transition David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the chair of its board of directors, David L. Lacey, M.D., stepped down as board chair at the ...

 PRESS RELEASE

Enliven Therapeutics Reports First Quarter Financial Results and Provi...

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focus...

 PRESS RELEASE

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data fr...

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024) Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors The oral presentation at EHA will include additional data at higher dose levels and longer treatment durations Company will host a webcas...

 PRESS RELEASE

RxSight, Inc. Announces Closing of its Public Offering of Common Stock...

RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase u...

David Carlson ... (+4)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

TScan Therapeutics Reports First Quarter 2024 Financial Results and Pr...

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months Closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026 WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic...

 PRESS RELEASE

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under N...

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees e...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch